Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ubrogepant

FDA-approved product (tablet, oral), marketed as Ubrelvy.

Registered studies
24
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ubrogepant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcitonin gene-related peptide (cgrp) antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ubrogepant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ubrogepant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

    NCT07680686 · start 2026-07-14

    Registered record
    Registry ID
    NCT07680686
    Conditions
    Healthy Volunteer
    Interventions
    Ubrogepant; Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-07-14
    Completion
    2026-10
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionUbrogepant; Ubrogepant
    PhasePhase 1
    Registry statusRecruiting

  • Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks

    NCT07310290 · start 2026-01-27

    Registered record
    Registry ID
    NCT07310290
    Conditions
    Migraine
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-01-27
    Completion
    2027-03
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada

    NCT06692881 · start 2025-02-12

    Registered record
    Registry ID
    NCT06692881
    Conditions
    Migraine
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-02-12
    Completion
    2026-06-01
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

    NCT06578585 · start 2024-09-13

    Registered record
    Registry ID
    NCT06578585
    Conditions
    Migraine
    Interventions
    Ubrogepant; Lu AG09222; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-09-13
    Completion
    2025-07-11
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionUbrogepant; Lu AG09222; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

    NCT06417775 · start 2024-09-10

    Registered record
    Registry ID
    NCT06417775
    Conditions
    Migraine
    Interventions
    Ubrogepant; Placebo for Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-09-10
    Completion
    2027-11
    Enrolment
    496

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionUbrogepant; Placebo for Ubrogepant
    PhasePhase 3
    Registry statusActive not recruiting

  • Migraine Medication Effects on Urinary Symptoms

    NCT06212661 · start 2024-04-05

    Registered record
    Registry ID
    NCT06212661
    Conditions
    Overactive Bladder; Bladder Pain Syndrome; Migraine Disorders; Overactive Bladder Syndrome; Overactive Detrusor; Migraine; Interstitial Cystitis
    Interventions
    Ubrogepant; Rimegepant; Atogepant; Eptinezumab; Fremanezumab; Galcanezumab; Erenumab; Botulinum toxin A
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2024-04-05
    Completion
    2026-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder; Bladder Pain Syndrome; Migraine Disorders; Overactive Bladder Syndrome +3 more
    InterventionUbrogepant; Rimegepant; Atogepant; Eptinezumab +4 more
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

    NCT05892757 · start 2023-07-11

    Registered record
    Registry ID
    NCT05892757
    Conditions
    Healthy Volunteers
    Interventions
    Atogepant; Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-07-11
    Completion
    2024-02-22
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAtogepant; Ubrogepant
    PhasePhase 1
    Registry statusCompleted

  • An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants

    NCT05827887 · start 2023-06-25

    Registered record
    Registry ID
    NCT05827887
    Conditions
    Migraine
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-06-25
    Completion
    2026-01-28
    Enrolment
    226

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

    NCT05158894 · start 2023-01-10

    Registered record
    Registry ID
    NCT05158894
    Conditions
    Migraine
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-01-10
    Completion
    2036-01
    Enrolment
    1,884

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

    NCT05653986 · start 2022-12-18

    Registered record
    Registry ID
    NCT05653986
    Conditions
    Migraine
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-12-18
    Completion
    2024-08-05
    Enrolment
    391

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

    NCT05503082 · start 2022-09-06

    Registered record
    Registry ID
    NCT05503082
    Conditions
    Headache, Migraine
    Interventions
    Ubrogepant 50 MG [Ubrelvy]; Ubrogepant 100 MG [Ubrelvy]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-09-06
    Completion
    2024-11
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeadache, Migraine
    InterventionUbrogepant 50 MG [Ubrelvy]; Ubrogepant 100 MG [Ubrelvy]
    PhasePhase 4
    Registry statusUnknown

  • Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine

    NCT05214001 · start 2022-06-30

    Registered record
    Registry ID
    NCT05214001
    Conditions
    Migraine With Aura; Migraine Without Aura
    Interventions
    Almotriptan 12.5 Mg Oral Tablet; Ubrogepant 50Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2022-06-30
    Completion
    2024-04-15
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine With Aura; Migraine Without Aura
    InterventionAlmotriptan 12.5 Mg Oral Tablet; Ubrogepant 50Mg Tab
    PhasePhase 4
    Registry statusTerminated

  • Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin

    NCT05654298 · start 2022-03-15

    Registered record
    Registry ID
    NCT05654298
    Conditions
    Migraine
    Interventions
    Sumatriptan; Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-03-15
    Completion
    2023-03-15
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionSumatriptan; Ubrogepant
    PhaseNot applicable
    Registry statusCompleted

  • Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

    NCT05264129 · start 2022-03-07

    Registered record
    Registry ID
    NCT05264129
    Conditions
    Episodic Migraine
    Interventions
    Atogepant; Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-03-07
    Completion
    2023-04-04
    Enrolment
    263

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpisodic Migraine
    InterventionAtogepant; Ubrogepant
    PhasePhase 4
    Registry statusCompleted

  • Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

    NCT05127954 · start 2022-01-14

    Registered record
    Registry ID
    NCT05127954
    Conditions
    Migraine
    Interventions
    Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2022-01-14
    Completion
    2028-01
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionUbrogepant
    PhasePhase 3
    Registry statusEnrolling by invitation